Ann: Letter to Shareholders, page-243

Great analogy J8 as always but that is end game stuff, as most of us are waiting short term movement.

Ongoing analyses of BIT225-009 samples and data are in

progress to further characterise the observed unique effects
of BIT225 in patients. Work is also underway to refine the
regulatory and developmental pathway to Phase 3 and
beyond.

Common knowledge, Biotron cannot go into Phase 3 alone, it will be with a partner. IMHO only matter of time until this progresses and not for cure, best treatment on open market if it gets approved. SP should jump from next Ann.

The sharing of data with the scientific community is an
important step towards commercialising your Company’s
antiviral platform.

Can this be platform deal? Easier to work out the tax implications

Briefing potential partners in the
pharmaceutical industry on the trial outcomes is another key
step. These meetings with potential partners are not single
events, but involve multiple meetings, spread several
months. We believe that the successful results from this
study will facilitate commercialisation negotiations with​

these parties.

​